Chimerix, Inc. (CXF.F)

0,8150 0,0000 (0,00%) Ab 09:29AM CEST. Markt geöffnet.

Chimerix, Inc.

2505 Meridian Parkway
Suite 100
Durham, NC 27713
United States
919-806-1074
https://www.chimerix.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 72

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Michael T. Andriole M.B.A.	CEO, President & Director	554,21k	N/A	1973
Dr. Allen S. Melemed M.B.A., M.D.	Chief Medical Officer	565,74k	N/A	1964
Ms. Michelle LaSpaluto	Chief Financial Officer	N/A	N/A	1975
Mr. Thomas J. Riga	Chief Operating & Commercial Officer	N/A	N/A	1976
Mr. David Jakeman CPA	VP of Accounting & Finance	N/A	N/A	1978
Dr. Joshua E. Allen Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Dr. Michael A. Alrutz J.D., Ph.D.	Senior VP, General Counsel & Corporate Secretary	579,02k	N/A	1970
Dr. Roy W. Ware MBA, Ph.D.	Chief Manufacturing Technology Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Corporate Governance

Chimerix, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 8. Die grundlegenden Scores sind Audit: 9, Vorstand: 7, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.